Micrograph of lichen sclerosus. Credit: Nephron.

Galapagos has commenced the NOVESA Phase IIa trial to assess the efficacy, safety and pharmacokinetic / pharmacodynamic (PK/PD) of GLPG1690 for the treatment of patients with systemic sclerosis (SSc) or scleroderma.

The double-blind and placebo-controlled trial is expected to enrol 30 patients with diffuse cutaneous SSc, an autoimmune disease involving multiorgan fibrosis and has no approved drugs for its treatment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Patients with diffuse cutaneous SSc are at a higher risk of developing fibrosis of several internal organs, including the lungs.

The primary objective of the NOVESA trial is the improved Rodnan skin score (mRSS) at 24 weeks.

“Thanks to the broad MoA of ‘1690, this compound has the potential to address the important unmet medical need in SSc.”

mRRS is designed to assess the skin thickness as a surrogate measure of disease severity and mortality.

The trial’s secondary objectives and exploratory goals comprise forced vital capacity (FVC), high-resolution computed tomography (HRCT), quality of life as assessed by quality of life questionnaire (QoL-Q), and combined response index for systemic sclerosis (CRISS).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Galapagos chief medical officer Dr Walid Abi-Saab said: “In addition to our Phase III programme in IPF, we are excited to broaden our development program with ‘1690 to a second indication.

“Moreover, SSc is particularly interesting, as this disease straddles our expertise in autoimmune diseases as well as in fibrosis.

“Thanks to the broad MoA of ‘1690, which is both anti-inflammatory and anti-fibrotic, this compound has the potential to address the important unmet medical need in SSc.”

SSc is currently estimated to affect nearly 90,000 patients in the US and Europe.